Key result
Combining PEGylated growth factors and lisinopril increases acute radiation survival by ~140% in rats.
Why the study?
Countermeasures are needed to mitigate lethal acute radiation syndrome (ARS) and delayed effects of acute radiation exposure (DEARE), as no monotherapy has demonstrated efficacy to mitigate both sets of injuries.
Does polypharmacy (hematopoietic growth factors, enrofloxacin, saline, and lisinopril) improve survival from acute and delayed radiation syndromes in irradiated rats?
Does polypharmacy (hematopoietic growth factors, enrofloxacin, saline, and lisinopril) improve survival from acute and delayed radiation syndromes in irradiated rats?
Absolute Event Rate: 60% vs 25%
p-value: p=0.05
A polypharmacy approach including hematopoietic growth factors and lisinopril effectively mitigates lethal acute and delayed radiation syndromes in a rat model.
Supports testing polypharmacy regimens in larger models; leaves open translation to human radiation countermeasures.
There is a need for countermeasures to mitigate lethal acute radiation syndrome (ARS) and delayed effects of acute radiation exposure (DEARE). In WAG/RijCmcr rats, ARS occurs by 30-days following total body irradiation (TBI), and manifests as potentially lethal gastrointestinal (GI) and hematopoietic (H-ARS) toxicities after >12.5 and >7 Gy, respectively. DEARE, which includes potentially lethal lung and kidney injuries, is observed after partial body irradiation >12.5 Gy, with one hind limb shielded (leg-out PBI). The goal of this study is to enhance survival from ARS and DEARE by polypharmacy, since no monotherapy has demonstrated efficacy to mitigate both sets of injuries. For mitigation of ARS following 7.5 Gy TBI, a combination of three hematopoietic growth factors (polyethylene glycol (PEG) human granulocyte colony-stimulating factor (hG-CSF), PEG murine granulocyte-macrophage-CSF (mGM-CSF), and PEG human Interleukin (hIL)-11), which have shown survival efficacy in murine models of H-ARS were tested. This triple combination (TC) enhanced survival by 30-days from ∼25% to >60%. The TC was then combined with proven medical countermeasures for GI-ARS and DEARE, namely enrofloxacin, saline and the angiotensin converting enzyme inhibitor, lisinopril. This combination of ARS and DEARE mitigators improved survival from GI-ARS, H-ARS, and DEARE after 7.5 Gy TBI or 13 Gy PBI. Circulating blood cell recovery as well as lung and kidney function were also improved by TC + lisinopril. Taken together these results demonstrate an efficacious polypharmacy to mitigate radiation-induced ARS and DEARE in rats.
No takes yet. Share an insight, caveat, or question.
Gasperetti et al. (2021) studied Acute Radiation Syndrome (ARS) and Delayed Effects of Acute Radiation Exposure (DEARE) (n=326). Triple combination (PEG-hG-CSF, PEG mGM-CSF, PEG hIL-11) and lisinopril vs. Vehicle or radiation alone was evaluated on 30-day survival after 7.5 Gy total body irradiation (p=0.05). A polypharmacy approach combining three PEGylated hematopoietic growth factors and lisinopril improved survival from acute radiation syndrome and delayed effects of acute radiation exposure in rats.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: